Try our beta test site

A Four-Week Multicenter Study Evaluating the Safety and Efficacy of AF-219 in Subjects With Osteoarthritis of the Knee

This study has been completed.
Information provided by (Responsible Party):
Afferent Pharmaceuticals, Inc. Identifier:
First received: March 12, 2012
Last updated: January 6, 2014
Last verified: January 2014

The purpose of this study is to assess the efficacy of a single dose level of AF-219 in subjects with moderate to severe pain associated with osteoarthritis (OA) of the knee compared with placebo after 4 weeks of treatment.

The study will also assess the safety and tolerability, changes in physical function, stiffness, global assessment of OA, treatment response and health outcomes.

Condition Intervention Phase
Osteoarthritis of the Knee
Drug: AF-219
Drug: Sugar Pill
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Afferent Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • The primary efficacy endpoint of this study is change from Baseline (Week 4 to Baseline) of the weekly average daily NPRS (average pain) [ Time Frame: 4 Weeks ]

Secondary Outcome Measures:
  • WOMAC Scores [ Time Frame: 4 Weeks ]
  • Daily Pain Scores [ Time Frame: 4 Weeks ]
  • Patient Global Assessment of Osteoarthritis [ Time Frame: 4 Weeks ]
  • Patient's and Clinician's Global Impression of Change [ Time Frame: 4 Weeks ]
  • Rescue medication usage [ Time Frame: 4 Weeks ]
  • Withdrawal for lack of efficacy [ Time Frame: 4 Weeks ]
  • SF-36 [ Time Frame: 4 Weeks ]

Enrollment: 190
Study Start Date: March 2012
Study Completion Date: December 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Sugar pill Drug: Sugar Pill
Experimental: AF-219 Drug: AF-219

Detailed Description:

Subjects who satisfy entry criteria at Screening will enter the Washout Phase, discontinuing their current nonsteroidal anti-inflammatory drug (NSAID) therapy.

Up to 220 subjects who fulfill flare (and other entry) criteria will be randomized to AF-219 or placebo.

Subjects will complete Treatment Visits 1, 2, 3, and 4 weeks after starting study drug. At each Treatment Visit, subjects will undergo efficacy assessments and safety procedures. During the Washout and Treatment Phases subjects will complete the 'average pain' Numeric Pain Rating Scale (NPRS) and count of rescue medication used for the preceding 24 hours.

Subjects will return 2 weeks after their last Treatment Visit (for a Follow-Up Visit).


Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men or women
  • Women of child bearing potential must not be pregnant during the study and must use two forms of birth control
  • Men and their female partners must use two forms of birth control
  • Clinical and radiographic evidence of chronic knee osteoarthritis
  • Minimum pain at Screening and during Washout
  • Ambulatory
  • Have provided written informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01554579

  Show 34 Study Locations
Sponsors and Collaborators
Afferent Pharmaceuticals, Inc.
  More Information

Responsible Party: Afferent Pharmaceuticals, Inc. Identifier: NCT01554579     History of Changes
Other Study ID Numbers: AF219-004 
Study First Received: March 12, 2012
Last Updated: January 6, 2014

Additional relevant MeSH terms:
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases processed this record on February 20, 2017